Skip to content Skip to footer
Subscribe Now
Spotlight Interview_Ana Cerdeira
EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Ana Cerdeira

Ana Cerdeira, Vice President, Global Head Commercial, Development Assets, Innovative Medicines Group, Grunenthal in a stimulating conversation with PharmaShots’ Managing Director Himanshu Sehgal. Ana will be joining the upcoming Reuters Events Pharma 2025 as a panelist for the topic “Value unleashed: Elevate patient, HCP, and payer engagement with holistic storytelling tools and RWE”. In this…
April 8, 2025

Read more

Key Biosimilars Events of March 2025
INSIGHTS+

Key Biosimilars Events of March 2025

Shots:        Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency         Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients         Bio-Thera Collaborates with Dr. Reddy’s for the Commercialization of BAT2206 & BAT2506…
April 8, 2025

Read more

Spotlight Interview_Philippe Barillon
EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Philippe Barillon

Philippe Barillon joins PharmaShots Managing Editor Himanshu Sehgal for an enlightening dialogue exchange in a Pre-Conference Talk. Philippe will be joining the upcoming Reuters Events Pharma 2025 as a panelist for the topic “Bridging gaps: Leverage data, tech and RWE for enhanced healthcare access and market growth”. Philippe highlights the potential applications of RWEs using…
April 7, 2025

Read more

Viewpoints_Raphaël Ortiz
VIEWPOINTS

Enhancing Diagnostic Capabilities in Prostate Cancer: Raphaël Ortiz from Telix Pharmaceuticals in a Riveting Conversation with PharmaShots

Shots:  Telix Pharmaceuticals’ Illuccix is approved in the UK for detecting and localizing prostate-specific membrane antigen (PSMA)-positive lesions in adults with prostate cancer, using PET imaging.  Amidst a shortage of PET imaging agents in the UK and mainland Europe, Telix Pharmaceuticals has secured a significant advantage through an exclusive distribution partnership with Xiel Limited  Raphaël…
April 7, 2025

Read more

Spotlight Interview_Konrad Dobschuetz
EVENTS

Reuters Pharma 2025: Pre-Conference Talks Featuring Konrad Dobschuetz

Konrad Dobschuetz, Founder Director at Leap Advisory & Intelligence will be conducting a workshop at the upcoming Reuters Events Pharma 2025 on the topic “Patient Centricity”. In the exclusive discussion with PharmaShots, Konrad addresses the need for biopharma companies to achieve a patient mindset to deliver patient-centric care and enhance the patient experience. Konrad believes…
April 4, 2025

Read more

Know Your Investor: Janus Henderson Group Plc (April’25 Edition)
INSIGHTS+

Know Your Investor: Janus Henderson Group Plc (April’25 Edition)

Shots:    Welcome to the 2025 series of Know Your Investor, featuring top venture capital firms focused on healthcare.  This edition highlights Janus Henderson Group Plc, a global investment firm managing approximately $378.7B in assets across Equities, Fixed Income, Multi-Asset, and Alternatives.  In 2024, the firm invested $5.36B across six funding rounds, adding 39 healthcare and…
April 3, 2025

Read more

Viewpoints_Roger Levy
VIEWPOINTS

Evaluating SDoH in Lupus Nephritis: Roger Levy from GSK in a Stimulating Conversation with PharmaShots

Shots:  GSK presented data at the American College of Rheumatology from a multi-center cohort study highlighting the achievement of complete renal response in patients with active lupus nephritis  The study evaluated the attainment of modified complete renal response (mCRR) in patients with systemic lupus erythematosus (SLE) and active lupus nephritis (LN), comparing characteristics between mCRR…
April 2, 2025

Read more

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2025

Shots:   Q1’2025 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The talk of the town remained Intra-Cellular Therapies’ acquisition by Johnson & Johnson for ~$14.6B   The quarter highlighted breakthrough results, pivotal clinical data, including Eli Lilly and Incyte's P-III Study Data of Baricitinib to treat Alopecia Areata  PharmaShots brings…
April 1, 2025

Read more

Spotlight Interview_Rahul Mittal
EVENTS

Reuters Pharma USA 2025: Post-Conference Talks featuring Rahul Mittal

Brimming with insightful panel discussions, presentations on disruptive technologies, and illuminating real-world evidence shaping the healthcare landscape now and then, the two-day Reuters event celebrated pharmaceutical innovation and fresh perspectives pouring into the interactive sessions. In the panel discussion at Reuters Pharma USA 2025, Rahul Mittal outlined ways to enhance patient centricity and engagement. Rahul…
March 31, 2025

Read more

CXO TALKS

CXO Talks: Heba Nowyhed from Arcellx in a Candid Conversation with PharmaShots

CAR T-cell therapies hold a promising foothold in addressing unmet healthcare needs. Arcellx, a clinical-stage biotech company, is steadfastly exploring the potential of cell therapy in RRMM and generalized myasthenia gravis patients with its lead asset anito-cel. During presentations at ASH, anito-cel demonstrated no delayed neurotoxicity in both P-1 and pivotal P-II clinical trials for multiple myeloma.…
March 28, 2025

Read more

Load more